27 December 2002
Clinical outcomes and costs of Amplatzer transcatheter closure as compared with surgical closure of ostium secundum atrial septal defects.
Jeffrey J. Kim, Ziyad M. HijaziMed Sci Monit 2002; 8(12): CR787-791 :: ID: 4811
Abstract
BACKGROUND: Transcatheter implantation of the Amplatzer septal occluder (ASO) is an alternative to conventional surgical closure of isolated secundum atrial septal defects (ASDs). Neither the clinical outcomes nor the costs of these procedures have been extensively compared. MATERIAL/METHODS: We performed a retrospective cohort study to evaluate cost-effectiveness in patients with secundum ASDs who underwent closure using either placement of an ASO or surgery. We utilized available TSI accounting data to estimate hospital costs. RESULTS: On the basis of trans-thoracic echocardiography, the procedures resulted in successful closure of the ASDs in 95.8% of patients in whom the ASO was implanted and 96.8% of surgical patients. Although there were no deaths in either group, complications occurred in 10.4% of patients in whom the ASO was implanted and 31.2% of surgical patients. The mean estimated cost per case treated with the ASO was $11,541 as compared with $21,780 for surgery. The average length of hospital stay per case treated with the ASO was 1.0 day as compared with 4.3 days for surgery. Sensitivity analyses based on our data identified no plausible situations in which the costs of surgery and of implantation of the ASO would be equal. CONCLUSIONS: The equally effective and less costly Amplatzer Septal Occluder appears superior to surgical closure of isolated secundum ASDs in qualifying patients. The transcatheter method is also associated with significantly lower morbidity. Consequently, our results support the use of the ASO as an alternative to surgery for the management of this common congenital lesion.
Keywords: Cardiac Surgical Procedures - economics, Heart Septal Defects, Atrial - surgery
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952